δ-Hydroxy-β-lysin

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: δ-Hydroxy-β-lysin
• 英文别名: (3R,5R)-3,6-diamino-5-hydroxyhexanoic acid
• 化学式: C₆H₁₄N₂O₃
• 分子量: 162.189
• InChiKey: LCWXJXMHJVIJFK-RFZPGFLSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.6
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  110
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  δ-Hydroxy-β-lysin 在 磷化氢 、 氢碘酸 作用下， 生成 (R)-β-lysine
  参考文献：
  名称：

  金霉素类似物的合成和性质修饰了δ-羟基-β-赖氨酸部分。

  摘要：

  DOI：

  10.7164/antibiotics.29.208
• 作为产物：
  描述：

  2-[[(3,6-二氨基-5-羟基己烷酰基)氨基]-甲基氨基]乙酸 在 盐酸 作用下， 生成 δ-Hydroxy-β-lysin
  参考文献：
  名称：

  Negamycin，一种新型的酰肼抗生素。

  摘要：

  DOI：

  10.1021/ja00752a072

文献信息

• Beta-amino acid derivatives useful for the treatment of bacterial infections
  申请人：——

  公开号：US20030125389A1

  公开（公告）日：2003-07-03

  The invention provides compounds that are useful for the treatment of bacterial infections in mammals. More specifically, it is directed to beta-amino acid derivatives or pharmaceutically acceptable salts, prodrugs, or isomers of 1 those compounds that are useful for the treatment of such infections.

  该发明提供了一些对哺乳动物细菌感染治疗有用的化合物。更具体地说，这些化合物是β-氨基酸衍生物或药用盐、前药或同分异构体，用于治疗这类感染。
• Structures of New Pseudo-Peptide Antibiotics, Sperabillins
  作者：Tsuneaki Hida、Shigetoshi Tsubotani、Yasunori Funabashi、Hideo Ono、Setsuo Harada

  DOI：10.1246/bcsj.66.863

  日期：1993.3

  Sperabillins, novel antibiotics, were isolated from the culture filtrate of Pseudomonas fluorescens YK-437. The structure of sperabillin A was elucidated to be 3-[[(3R,5R)-3-amino-6-[(2E,4Z)-2,4-hexadienoylamino]-5-hydroxyhexanoyl]amino]propanamidine dihydrochloride. Sperabillin B has a methyl substituent at the C-6 position of sperabillin A. Sperabillin C and D are (2E,4E)-isomers of the 2,4-hexadienoyl moiety of sperabillin A and B, respectively.

  从荧光假单胞菌 YK-437 的培养滤液中分离出了新型抗生素--斯佩拉比林。经阐明，斯佩拉比林 A 的结构为 3-[[(3R,5R)-3-氨基-6-[(2E,4Z)-2,4-己二烯酰氨基]-5-羟基己酰]氨基]丙脒二盐酸盐。sperabillin C 和 D 分别是 sperabillin A 和 B 的 2,4-己二烯酰基的 (2E,4E)-异构体。
• Administration of negamycin or deoxynegamycin for the treatment of bacterial infections
  申请人：——

  公开号：US20030109583A1

  公开（公告）日：2003-06-12

  The invention provides a method for treating bacterial infections. In one aspect, the invention comprises orally administering a pharmaceutical composition to an animal, wherein the composition comprises a pharmaceutically acceptable excipient and an antibacterial effective amount of negamycin, or a pharmaceutically acceptable salt, prodrug or isomer thereof. An aspect of the invention also relates to a method of treating a bacterial infection, wherein the method comprises intravenously administering a pharmaceutical composition to an animal, and wherein the composition comprises a pharmaceutically acceptable excipient and an antibacterial effective amount of deoxynegamycin, or a pharmaceutically acceptable salt, prodrug or isomer thereof. An aspect of the invention also relates to a method of treating a bacterial infection, wherein the method comprises administering to an animal an antibacterial effective amount of negamycin or deoxynegamycin, or a pharmaceutically acceptable salt, prodrug or isomer thereof, and wherein the infecting bacteria are selected from a group of bacteria consisting of the following: Acinetobacter baumanii, Citrobacter freundii, Enterobacter aerogenes, haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus MRSA, Staphylococcus aureus GISA, Staphylococcus epidermis, Streptococcus pneumoniae PenR, Streptococcus pneumoniae PenS and Streptococcus pyogenes.

  本发明提供了一种治疗细菌感染的方法。在一方面，本发明涉及向动物口服含有一种药物组合物的方法，该组合物包括一种药学上可接受的赋形剂和一种抗菌有效量的奈加霉素，或其药学上可接受的盐、前药或同分异构体。本发明的另一方面涉及一种治疗细菌感染的方法，该方法包括向动物静脉注射一种药物组合物，该组合物包括一种药学上可接受的赋形剂和一种抗菌有效量的去氧奈加霉素，或其药学上可接受的盐、前药或同分异构体。本发明的另一方面涉及一种治疗细菌感染的方法，该方法包括向动物施用一种抗菌有效量的奈加霉素或去氧奈加霉素，或其药学上可接受的盐、前药或同分异构体，其中感染细菌被选自以下细菌组：鲍曼不动杆菌，弗氏柠檬酸杆菌，肺炎克雷伯菌，流感嗜血杆菌，卡他莫拉菌，金黄色葡萄球菌MRSA，金黄色葡萄球菌GISA，表皮葡萄球菌，肺炎链球菌PenR，肺炎链球菌PenS和链球菌。
• TAN-1511, its derivatives, production and use thereof
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0604945A1

  公开（公告）日：1994-07-06

  A compound of the formula: wherein each R¹, R² and R³ is an aliphatic acyl group, X is an amino acid sequence consisting of 1 to 5 amino acid residues which contain at least one acidic amino acid residue, n is an integer of 0 to 4, provided that when n is 0, X has glutamyl-glycyl at its N-terminal and when n is 1 or 2, the acidic amino acid residue is an acidic amino acid residue other than D-glutamyl, or a salt thereof has an activity of remarkably improving anhematopoiesis and is useful as an immuno-stimulating agent having a leukocyte-increasing activity.

  式中的化合物： 其中每个 R¹、R² 和 R³ 是脂肪族酰基，X 是由 1 至 5 个氨基酸残基组成的氨基酸序列，其中至少含有一个酸性氨基酸残基，n 是 0 至 4 的整数，条件是当 n 为 0 时，X 的 N 端具有谷氨酰-甘氨酰，当 n 为 1 或 2 时，X 的 N 端具有谷氨酰-甘氨酰、酸性氨基酸残基是除 D-谷氨酰以外的酸性氨基酸残基，或其盐具有显著改善造血功能的活性，可用作具有增加白细胞活性的免疫刺激剂。
• 2-Amino-6,7-dihydroxy-4-thiaheptanoic acid derivatives, production and use thereof
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0604957A1

  公开（公告）日：1994-07-06

  A compound of the formula: wherein each of R1 and R2 is hydrogen or aliphatic acyl, A is amino which may be protected, X is an amino acid sequence consisting of 1 to 10 amino acid residues which contain at least one amino acid residue having a water-solubility enhancing group, or a salt thereof has an activity of remarkably improving hematopoietic disorder and is useful as an immuno-stimulating agent or an agent for treating thrombocytopenia.

  式中的化合物： 其中 R1 和 R2 均为氢或脂族酰基，A 为可被保护的氨基，X 为由 1 至 10 个氨基酸残基组成的氨基酸序列，其中至少含有一个具有水溶性增强基团的氨基酸残基，或其盐具有显著改善造血障碍的活性，可用作免疫刺激剂或治疗血小板减少症的药物。